Chase Investment Counsel Corp Acquires 259 Shares of Merck & Co., Inc. (NYSE:MRK)

Chase Investment Counsel Corp lifted its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 3.2% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,360 shares of the company’s stock after purchasing an additional 259 shares during the period. Chase Investment Counsel Corp’s holdings in Merck & Co., Inc. were worth $1,103,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Hudock Inc. raised its stake in Merck & Co., Inc. by 10.5% during the 1st quarter. Hudock Inc. now owns 26,764 shares of the company’s stock worth $3,532,000 after acquiring an additional 2,538 shares during the period. Summit Financial Wealth Advisors LLC raised its stake in Merck & Co., Inc. by 2.2% during the 1st quarter. Summit Financial Wealth Advisors LLC now owns 73,985 shares of the company’s stock worth $9,762,000 after acquiring an additional 1,605 shares during the period. Magnolia Capital Advisors LLC raised its stake in Merck & Co., Inc. by 10.6% during the 1st quarter. Magnolia Capital Advisors LLC now owns 17,640 shares of the company’s stock worth $2,219,000 after acquiring an additional 1,685 shares during the period. FinTrust Capital Advisors LLC raised its stake in Merck & Co., Inc. by 11.7% during the 1st quarter. FinTrust Capital Advisors LLC now owns 9,712 shares of the company’s stock worth $1,281,000 after acquiring an additional 1,019 shares during the period. Finally, Wright Investors Service Inc. raised its position in shares of Merck & Co., Inc. by 3.0% during the first quarter. Wright Investors Service Inc. now owns 39,022 shares of the company’s stock valued at $5,149,000 after buying an additional 1,120 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Up 0.2 %

NYSE MRK opened at $126.08 on Wednesday. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. The company has a fifty day moving average of $128.99 and a two-hundred day moving average of $125.39. The firm has a market capitalization of $319.34 billion, a price-to-earnings ratio of 140.09, a PEG ratio of 2.43 and a beta of 0.38. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $134.63.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The business’s revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.40 earnings per share. On average, analysts predict that Merck & Co., Inc. will post 8.62 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, July 8th. Investors of record on Monday, June 17th were issued a $0.77 dividend. The ex-dividend date was Monday, June 17th. This represents a $3.08 annualized dividend and a dividend yield of 2.44%. Merck & Co., Inc.’s payout ratio is currently 342.22%.

Analysts Set New Price Targets

MRK has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price objective on shares of Merck & Co., Inc. in a research report on Tuesday, June 18th. Berenberg Bank lifted their price objective on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Wells Fargo & Company lifted their price objective on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 27th. Argus upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, June 5th. Finally, Truist Financial lifted their price objective on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $133.00.

Get Our Latest Report on Merck & Co., Inc.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.